Relationship between serum concentration of linezolid and efficacy and side effects in elderly patients with severe infection

Conditions

Severe infection

Yaping Yuan, Tingting Liu, Xia Wu, Xiaoxiao Duan, Cheng Zhao et al. (16 authors)

BMC Pharmacology and Toxicology2026-08-11

Effects of Different Linezolid Concentration Levels on Hematologic Side Effects: A New Target for Therapeutic Drug Monitoring

Tingting Liu, Bing Liu, Guangrui Geng, Ping Yang, Zidu Wang et al. (15 authors)

Therapeutic Drug Monitoring2025-08-15

10.1097/ftd.0000000000001364

Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study

Tingting Liu, Yaping Yuan, Chao Wang, Jionghe Wu, Yajuan Wang et al. (16 authors)

Journal of Antimicrobial Chemotherapy2024-06-1419 citations

10.1093/jac/dkae188

Interventions

Thrombocytopenia group:Nil

Non-thrombocytopenia group:Nil

Eligibility

Sex/Gender

All

Age

60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=85 years; 2. Diagnosis or suspected G+ bacteria infection, including MRSA, MSSA, VRE, VRSA, etc.; 3. Patients treated with linezolid.

Exclusion criteria

Exclusion criteria: 1. Use chemotherapy or tigecycline and other drugs that inhibit bone marrow; use metformin, nucleotide reverse transcriptase inhibition and other drugs that affect lactic acid; 2. Receive renal replacement therapy; 3. Linezolid use <3 days; 4. The expected survival period is less than 7 days.

Design outcomes

Primary

Measure	Time frame
Blood concentration of linezolid;	—

Countries

china

Contacts

Public ContactLi Hongxia

Chinese PLA General Hospital

lhxsls@sina.com+86 18501328669

Outcome results

None listed